Research

Hormonal

Oral semaglutide 14 mg daily produces clinically significant weight loss (≥5%) in approximately half of non-diabetic obese adults, with an average loss of 5.7% and a favorable safety profile, though it is less effective than injectable semaglutide or tirzepatide.

If you are obese and do not have diabetes, taking 14mg of oral semaglutide daily for a year will likely result in about 6% body weight loss on average. While not as powerful as the injectable version, it is a safe option if you dislike injections or cannot access injectable medications. Expect mild nausea in some cases, but serious side effects are rare.

ModerateQualifiesMEDIUM confidence
After one year of treatment body weight was significantly lower by 5.7% (5.9 kg) in completers... Clinically significant weight loss was achieved in 46% of all participants... Although less effective than injectable therapy, oral semaglutide at a dose of 14 mg had a favorable safety profile and may be suitable in selected clinical scenarios.
Mitja Krajnc et al. · Frontiers in Endocrinology · 2025

Why this rating

Real-world retrospective observational study; lacks randomization and control group, introducing selection bias.

Source

Oral semaglutide for the treatment of obesity: a retrospective real-world study

Mitja Krajnc et al. · Frontiers in Endocrinology · 2025

DOI 10.3389/fendo.2025.1593334

cohort · n=93Cited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →